B-type natriuretic peptides: Looking to the future

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals medicus

• Publication date

  2011-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/07853890.2010.526630PMID 20961274
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulation Editors' Picks: Most Read Articles on the Topic of Biomarkers

  2012cited by this paper
• A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts

  2010cited by this paper
• Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.

  2010cited by this paper
• Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

  2010cited by this paper
• B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia

  2010cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

  2010cited by this paper
• Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery

  2010cited by this paper
• B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.

  2010cited by this paper
• Randomized comparison between clinical evaluation plus N-terminal pro-B-type natriuretic peptide versus exercise testing for decision making in acute chest pain of uncertain origin.

  2010cited by this paper
• Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.

  2010cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

  2009influential reference
• N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study.

  2009cited by this paper
• B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies

  2009cited by this paper
• Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study

  2009cited by this paper
• Prognostic value of natriuretic peptides in Chagas' disease: a head-to-head comparison of the 3 natriuretic peptides.

  2009cited by this paper
• The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study.

  2009cited by this paper
• Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide

  2009cited by this paper
• Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies.

  2009cited by this paper
• BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

  2009cited by this paper
• Brain natriuretic peptide a predictive marker in cardiac surgery.

  2009cited by this paper
• N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome.

  2009cited by this paper
• Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.

  2009cited by this paper
• Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea.

  2009cited by this paper
• Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.

  2009cited by this paper
• N-terminal pro-B-type natriuretic peptide concentrations and long-term outcome after cardiac surgery: a prospective cohort study.

  2009cited by this paper
• Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management?

  2009cited by this paper
• Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery

  2009cited by this paper
• N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements.

  2008cited by this paper
• Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

  2008cited by this paper
• Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure

  2008cited by this paper
• Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction

  2008cited by this paper
• Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study.

  2008cited by this paper
• Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

  2007cited by this paper
• N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study

  2007cited by this paper
• N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.

  2007cited by this paper
• Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.

  2007cited by this paper
• National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure.

  2007cited by this paper
• B-type natriuretic peptide infusions in acute myocardial infarction

  2007cited by this paper
• Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide.

  2007cited by this paper
• Chronic Kidney Disease: Effects on the Cardiovascular System

  2007cited by this paper
• Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department.

  2006cited by this paper
• Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.

  2006cited by this paper
• Use of B-type natriuretic peptide in the detection of myocardial ischemia.

  2006cited by this paper
• National trends in outcomes among elderly patients with heart failure.

  2006cited by this paper
• Diastolic Function in Young Patients with Beta‐Thalassemia Major: An Echocardiographic Study

  2006cited by this paper
• Does this dyspneic patient in the emergency department have congestive heart failure?

  2005cited by this paper
• Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.

  2005cited by this paper
• Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients.

  2005cited by this paper
• Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3,5-Monophosphate and Decreases Mean Arterial Pressure

  2005cited by this paper
• N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

  2005cited by this paper
• Plasma BNP in patients on maintenance haemodialysis: a guide to management?

  2005cited by this paper
• Nesiritide - not verified.

  2005cited by this paper
• Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice

  2005cited by this paper
• Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus.

  2004cited by this paper
• N‐terminal pro‐brain natriuretic peptide for discriminating between cardiac and non‐cardiac dyspnoea

  2004cited by this paper
• Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction.

  2004cited by this paper
• Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

  2004cited by this paper
• Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.

  2004cited by this paper
• Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

  2003cited by this paper
• Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.

  2003cited by this paper
• Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

  2003cited by this paper
• Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease.

  2002cited by this paper
• Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths.

  2002cited by this paper
• Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

  2002cited by this paper
• Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide

  2002cited by this paper
• The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

  2001cited by this paper
• Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.

  2001cited by this paper
• INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE

  2000cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

  2000cited by this paper
• Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

  1999cited by this paper
• The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction.

  1997cited by this paper
• Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.

  1997cited by this paper
• Plasma brain natriuretic peptide in assessment of acute dyspnoea.

  1994cited by this paper
• Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation.

  1989cited by this paper
• The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: a longitudinal study.

  1988cited by this paper

• N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Populations Carrying Cardiovascular Risk Factors

  2019cites this paper
• Predictors of cardiomyopathy in patients with type-2 diabetes mellitus with and without cardiovascular complications: A cross-sectional study.

  2019cites this paper
• Marcadores biológicos: ¿ qué aportan los péptidos natriuréticos? Biological markers: What do the natriuretic peptides contribute?

  2016cites this paper
• Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction.

  2015cites this paper
• N‑terminal pro‑B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis.

  2015cites this paper
• Plasma B-type natriuretic peptide (BNP) in acute Puumala hantavirus infection

  2014cites this paper
• Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research

  2014cites this paper
• Biomarkers in acute medicine

  2013cites this paper
• Left ventricular global longitudinal strain in acute myocardial infarction--with special reference to neurohormonal activation, in-hospital heart failure and prognosis.

  2013cites this paper
• Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress

  2013cites this paper
• Biomarcadores en insuficiencia cardíaca: nuevos actores, nuevos conceptos

  2013cites this paper
• Marcadores biológicos, ¿qué aportan los péptidos natriuréticos?

  2012cites this paper
• Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

  2012cites this paper
• Relative Change in NT-proBNP Level: An Important Risk Predictor of Cardiovascular Congestion in Haemodialysis Patients

  2012cites this paper